文献速递主动脉疾病

炎性腹主动脉瘤开放与腔内修复的安全性和有效性:系统评价与Meta分析

Safety and Effectiveness of Open and Endovascular Repair for Inflammatory Abdominal Aortic Aneurysm: Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2025-05-02

该系统评价与Meta分析纳入19项研究共656例炎性腹主动脉瘤患者,比较EVAR与OSR的死亡率和围术期并发症。EVAR的30天死亡率为2.9%(95%CI 0.4-6.1%;I²=0%),OSR略高为9%(95%CI 5-15%;I²=58%)。作者认为两者均为可行治疗选择,OSR技术难度更高、并发症和死亡率更高,但肾积水缓解更明显。

要点

  • EVAR的30天死亡率为2.9%(95%CI 0.4-6.1%;I²=0%),OSR为9%(95%CI 5-15%;I²=58%)。
  • 术后肾积水EVAR为9.8%(95%CI 1.1-18.6%;I²=0%),OSR为6.1%(95%CI 3.4-8.9%;I²=0%)。
  • 作者认为OSR肾积水缓解更明显,EVAR围术期安全性更好但肾积水缓解较少。

核心结论

  • OSR和EVAR均为可行的治疗选择,选择应基于患者个体因素。
  • OSR技术难度更高、并发症和死亡率更高,但肾积水缓解更明显。
  • EVAR作为侵入性较小的替代方案,围术期安全性更好,但肾积水缓解较少。
  • 个体化手术策略和仔细的围术期管理至关重要。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、SCOPUS、ISI Web of Science和Cochrane数据库。
  • 纳入随机对照试验、非随机干预研究、病例对照试验、队列和病例系列研究。
  • 共纳入19项研究、656例患者。
  • 采用二分类共同效应和随机效应模型分析死亡率和并发症。
  • 使用美国国家心肺血液研究所和Risk of Bias 2工具评估研究质量。

主要发现

  • EVAR的30天死亡率为2.9%(95%CI 0.4-6.1%;I²=0%),OSR为9%(95%CI 5-15%;I²=58%)。
  • 术前肾积水EVAR为12.7%(95%CI 6.4-19.0%;I²=0%),OSR为16.5%(95%CI 12.9-20.2%;I²=0%)。
  • 术后肾积水EVAR为9.8%(95%CI 1.1-18.6%;I²=0%),OSR为6.1%(95%CI 3.4-8.9%;I²=0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory abdominal aortic aneurysm (IAAA) is a rare subtype of atherosclerotic aneurysms with a pronounced inflammatory response and high risk of perioperative complications. The optimal treatment remains uncertain. This systematic-review with meta-analysis aims to evaluate mortality and perioperative complications in IAAA patients undergoing endovascular repair (EVAR) or open surgical repair (OSR). METHODS: A systematic search of randomized controlled trials, nonrandomized interventional studies, case-controlled trials, cohorts, and case series studies was conducted in PubMed, SCOPUS, ISI Web of Science, and Cochrane databases. Mortality and complications were analyzed using binary common and random-effects models. Study quality was assessed with National Heart, Lung, and Blood Institute and Risk of Bias 2 tools. RESULTS: Nineteen studies (656 patients) were included. The pooled estimate of 30-day mortality for EVAR was 2.9% (95% confidence interval [CI]: 0.4-6.1%; I2 = 0%) and for OSR was slightly higher at 9% (95% CI: 5-15%; I2 = 58%). Preoperative hydronephrosis was 12.7% (95% CI: 6.4-19.0%; I2 = 0%) for EVAR and 16.5% (95% CI: 12.9-20.2%; I2 = 0%) for OSR. Postoperative hydronephrosis was 9.8% (95% CI: 1.1-18.6%; I2 = 0%) for EVAR and 6.1% (95% CI: 3.4-8.9%; I2 = 0%) for OSR. CONCLUSION: OSR and EVAR are viable treatment options, with the choice guided by patient-specific factors. While OSR is more technically demanding and carries higher morbidity and mortality, it results in greater hydronephrosis resolution. EVAR, as a less invasive alternative, offers a safer perioperative profile but achieves less pronounced hydronephrosis reduction. Personalized surgical strategies and careful perioperative management are crucial.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Finisterra-Rodrigues R, Pereira-Neves A, Dias-Neto M, et al. Safety and Effectiveness of Open and Endovascular Repair for Inflammatory Abdominal Aortic Aneurysm: Systematic Review and Meta-Analysis. Ann Vasc Surg. 2025. PMID: 40320205. doi:10.1016/j.avsg.2025.04.120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。